A hepatitis C avidity test for determining recent and past infections in both plasma and dried blood spots

Samantha J. Shepherd, Joy Keen, Sharon Hutchinson, Sheila O. Cameron, David J. Goldberg, W. Carman, R.N. Gunson, Celia Aitken

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

DBS testing has been used successfully to detect HCV antibody positive individuals. Determining how long someone has been infected is important for surveillance initiatives. Antibody avidity is a method that can be used to calculate recency of infection. A HCV avidity assay was evaluated for both plasma and DBS.
Study design: To measure antibody avidity a commercial HCV ELISA was modified using 7 M urea. The plasma samples were split into: group 1 (recently infected N = 19), group 2 (chronic carrier N = 300) and group 3 (resolved infection N = 82). Mock DBS made from group 1 (N = 12), group 2 (N = 50), group 3
(N = 25) and two seroconverter panels were evaluated. 133 DBS taken from patients known to have a resolved infection or be a chronic carrier were also tested. The avidity assay cut-off was set at AI ≤ 30 for a recent infection. Using sequential samples the assay could detect a recent infection in the first 4–5 months from the point of infection. Most of the false positive results (AI < 30 among cases known not to have had recent infection) were detected among
known resolved infections, in both the plasma and DBS; as a result, a testing algorithm has been designed incorporating both PCR and two dilution factors. The sensitivity and specificity of the assay on plasma was 100% and 99.3%, respectively, while DBS had 100% sensitivity and 98.3% specificity.
The HCV avidity assay can be used to distinguish between chronic and recent infection using either plasma or DBS as the sample type.
LanguageEnglish
Pages29-35
Number of pages7
JournalJournal of Clinical Virology
Volume57
Issue number1
Early online date28 Jan 2013
DOIs
Publication statusPublished - May 2013

Fingerprint

Hepatitis C
Infection
Antibody Affinity
Sensitivity and Specificity
Hepatitis C Antibodies
Urea
Enzyme-Linked Immunosorbent Assay
Polymerase Chain Reaction

Keywords

  • avidity
  • HCV
  • DBS
  • plasma
  • dried blood spots
  • hepatitis C avidity test
  • recent
  • chronic
  • resolved
  • infections

Cite this

Shepherd, S. J., Keen, J., Hutchinson, S., Cameron, S. O., Goldberg, D. J., Carman, W., ... Aitken, C. (2013). A hepatitis C avidity test for determining recent and past infections in both plasma and dried blood spots. Journal of Clinical Virology, 57(1), 29-35. https://doi.org/10.1016/j.jcv.2013.01.002
Shepherd, Samantha J. ; Keen, Joy ; Hutchinson, Sharon ; Cameron, Sheila O. ; Goldberg, David J. ; Carman, W. ; Gunson, R.N. ; Aitken, Celia. / A hepatitis C avidity test for determining recent and past infections in both plasma and dried blood spots. In: Journal of Clinical Virology. 2013 ; Vol. 57, No. 1. pp. 29-35.
@article{ff226c14f93c48e9bb9fb7005349d733,
title = "A hepatitis C avidity test for determining recent and past infections in both plasma and dried blood spots",
abstract = "DBS testing has been used successfully to detect HCV antibody positive individuals. Determining how long someone has been infected is important for surveillance initiatives. Antibody avidity is a method that can be used to calculate recency of infection. A HCV avidity assay was evaluated for both plasma and DBS.Study design: To measure antibody avidity a commercial HCV ELISA was modified using 7 M urea. The plasma samples were split into: group 1 (recently infected N = 19), group 2 (chronic carrier N = 300) and group 3 (resolved infection N = 82). Mock DBS made from group 1 (N = 12), group 2 (N = 50), group 3(N = 25) and two seroconverter panels were evaluated. 133 DBS taken from patients known to have a resolved infection or be a chronic carrier were also tested. The avidity assay cut-off was set at AI ≤ 30 for a recent infection. Using sequential samples the assay could detect a recent infection in the first 4–5 months from the point of infection. Most of the false positive results (AI < 30 among cases known not to have had recent infection) were detected amongknown resolved infections, in both the plasma and DBS; as a result, a testing algorithm has been designed incorporating both PCR and two dilution factors. The sensitivity and specificity of the assay on plasma was 100{\%} and 99.3{\%}, respectively, while DBS had 100{\%} sensitivity and 98.3{\%} specificity.The HCV avidity assay can be used to distinguish between chronic and recent infection using either plasma or DBS as the sample type.",
keywords = "avidity, HCV, DBS, plasma , dried blood spots, hepatitis C avidity test, recent, chronic, resolved, infections",
author = "Shepherd, {Samantha J.} and Joy Keen and Sharon Hutchinson and Cameron, {Sheila O.} and Goldberg, {David J.} and W. Carman and R.N. Gunson and Celia Aitken",
year = "2013",
month = "5",
doi = "10.1016/j.jcv.2013.01.002",
language = "English",
volume = "57",
pages = "29--35",
journal = "Journal of Clinical Virology",
issn = "1386-6532",
number = "1",

}

Shepherd, SJ, Keen, J, Hutchinson, S, Cameron, SO, Goldberg, DJ, Carman, W, Gunson, RN & Aitken, C 2013, 'A hepatitis C avidity test for determining recent and past infections in both plasma and dried blood spots' Journal of Clinical Virology, vol. 57, no. 1, pp. 29-35. https://doi.org/10.1016/j.jcv.2013.01.002

A hepatitis C avidity test for determining recent and past infections in both plasma and dried blood spots. / Shepherd, Samantha J.; Keen, Joy; Hutchinson, Sharon; Cameron, Sheila O.; Goldberg, David J.; Carman, W.; Gunson, R.N.; Aitken, Celia.

In: Journal of Clinical Virology, Vol. 57, No. 1, 05.2013, p. 29-35.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A hepatitis C avidity test for determining recent and past infections in both plasma and dried blood spots

AU - Shepherd, Samantha J.

AU - Keen, Joy

AU - Hutchinson, Sharon

AU - Cameron, Sheila O.

AU - Goldberg, David J.

AU - Carman, W.

AU - Gunson, R.N.

AU - Aitken, Celia

PY - 2013/5

Y1 - 2013/5

N2 - DBS testing has been used successfully to detect HCV antibody positive individuals. Determining how long someone has been infected is important for surveillance initiatives. Antibody avidity is a method that can be used to calculate recency of infection. A HCV avidity assay was evaluated for both plasma and DBS.Study design: To measure antibody avidity a commercial HCV ELISA was modified using 7 M urea. The plasma samples were split into: group 1 (recently infected N = 19), group 2 (chronic carrier N = 300) and group 3 (resolved infection N = 82). Mock DBS made from group 1 (N = 12), group 2 (N = 50), group 3(N = 25) and two seroconverter panels were evaluated. 133 DBS taken from patients known to have a resolved infection or be a chronic carrier were also tested. The avidity assay cut-off was set at AI ≤ 30 for a recent infection. Using sequential samples the assay could detect a recent infection in the first 4–5 months from the point of infection. Most of the false positive results (AI < 30 among cases known not to have had recent infection) were detected amongknown resolved infections, in both the plasma and DBS; as a result, a testing algorithm has been designed incorporating both PCR and two dilution factors. The sensitivity and specificity of the assay on plasma was 100% and 99.3%, respectively, while DBS had 100% sensitivity and 98.3% specificity.The HCV avidity assay can be used to distinguish between chronic and recent infection using either plasma or DBS as the sample type.

AB - DBS testing has been used successfully to detect HCV antibody positive individuals. Determining how long someone has been infected is important for surveillance initiatives. Antibody avidity is a method that can be used to calculate recency of infection. A HCV avidity assay was evaluated for both plasma and DBS.Study design: To measure antibody avidity a commercial HCV ELISA was modified using 7 M urea. The plasma samples were split into: group 1 (recently infected N = 19), group 2 (chronic carrier N = 300) and group 3 (resolved infection N = 82). Mock DBS made from group 1 (N = 12), group 2 (N = 50), group 3(N = 25) and two seroconverter panels were evaluated. 133 DBS taken from patients known to have a resolved infection or be a chronic carrier were also tested. The avidity assay cut-off was set at AI ≤ 30 for a recent infection. Using sequential samples the assay could detect a recent infection in the first 4–5 months from the point of infection. Most of the false positive results (AI < 30 among cases known not to have had recent infection) were detected amongknown resolved infections, in both the plasma and DBS; as a result, a testing algorithm has been designed incorporating both PCR and two dilution factors. The sensitivity and specificity of the assay on plasma was 100% and 99.3%, respectively, while DBS had 100% sensitivity and 98.3% specificity.The HCV avidity assay can be used to distinguish between chronic and recent infection using either plasma or DBS as the sample type.

KW - avidity

KW - HCV

KW - DBS

KW - plasma

KW - dried blood spots

KW - hepatitis C avidity test

KW - recent

KW - chronic

KW - resolved

KW - infections

UR - http://www.scopus.com/inward/record.url?scp=84875812852&partnerID=8YFLogxK

U2 - 10.1016/j.jcv.2013.01.002

DO - 10.1016/j.jcv.2013.01.002

M3 - Article

VL - 57

SP - 29

EP - 35

JO - Journal of Clinical Virology

T2 - Journal of Clinical Virology

JF - Journal of Clinical Virology

SN - 1386-6532

IS - 1

ER -